Single-nucleus RNA sequencing identifies brain cell types with significant changes in gene expression in autism

Although bulk transcriptional profiling studies of postmortem autism spectrum disorder (ASD) brain samples have identified shared changes in gene expression (e.g., Parikshak et al., Nature, 2016), little information has been available as to how these changes map to specific cell types. SFARI Investigator Arnold Kriegstein and colleagues now use single-nucleus RNA sequencing (snRNA-seq) to identify key cell types in the developing brain that show disproportionate dysregulation of gene expression, with enrichment for genes known to be involved in ASD risk.

In the new work, supported in part by a SFARI Pilot Award, Kriegstein’s team carried out snRNA-seq on 41 postmortem brain samples, including prefrontal cortex and anterior cingulate cortex, from 15 individuals with ASD and 16 controls. Unbiased clustering identified significant changes in gene expression, particularly in upper layer (layer 2/3) excitatory neurons, vasoactive intestinal polypeptide (VIP)-expressing interneurons, protoplasmic astrocytes and microglia. Moreover, there was a highly significant overlap in those genes showing dysregulated gene expression in the ASD samples and those that have been implicated in the etiology of ASD.

These data are consistent with previous work identifying layer 2/3 neurons as a cell type where high-confidence ASD risk factors exhibit convergent patterns of gene expression (Parikshak et al., Cell, 2013). Among the dysregulated genes is SOX5, which is noteworthy in light of its potential role in regulating the expression of the gene set that shows attenuated cortical patterning in the ASD brain (Parikshak et al., Nature, 2016). Finally, the authors show that individuals with different degrees of clinical severity, as measured by scores on the Autism Diagnostic Interview–Revised (ADI-R), clustered according to dysregulation of genes in layer 2/3 neurons and microglia.

Gene dysregulation in ASD correlates with clinical severity. Gene dysregulation in ASD correlates with clinical severity. Cell types ranked by correlation of differentially expressed genes with combined clinical scores, as assessed by the Autism Diagnostic Interview–Revised (ADI-R). Cell types labeled in green were significantly (P < 0.05) correlated with clinical severity. Image from Velmeshev D. et al. (2019).


Single-cell genomics identifies cell type-specific molecular changes in autism.

Velmeshev D., Schirmer L., Jung D., Haeussler M., Perez Y., Mayer S., Bhaduri A., Goyal N., Rowitch D.H., Kriegstein A.

Science 364, 685-689 (May 16, 2019) PubMed

Research Highlights